Functions of CAFs in microenvironment of non-small cell lung cancer: based on updated hallmarks of cancer

被引:1
|
作者
Feng, Xiaoyan [1 ]
Zhu, Binghan [3 ]
Peng, Yali [1 ]
Zhang, Kaiyuan [3 ]
Wang, Yangchun [1 ]
Huang, Guichun [2 ]
Li, Yan [1 ,3 ]
机构
[1] Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Med Sch,Dept Resp Med, Nanjing, Jiangsu, Peoples R China
[2] Nanjing Univ, Med Sch, Nanjing, Jiangsu, Peoples R China
[3] Nanjing Univ Chinese Med, Nanjing Drum Tower Hosp, Clin Coll, Dept Resp Med, Nanjing, Jiangsu, Peoples R China
关键词
non-small cell lung cancer; tumor microenvironment; cancer-associated fibroblasts; tumor biology; resistance to antineoplastic therapy; cancer hallmarks; DRUG-RESISTANCE; FIBROBLASTS; INVASION; PROMOTE; AXIS;
D O I
10.1515/oncologie-2024-0232
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer, which ranks as the first malignant tumor in mortality. The occurrence and development of NSCLC are closely related to the tumor microenvironment (TME). Cancer-associated fibroblasts (CAFs) in the tumor microenvironment are considered to be critical regulators of the occurrence and development of NSCLC, which have essential effects on multiple biological characteristics of NSCLC. The hallmarks of cancer biology have been updated recently, however, there are no reviews revisiting the function of CAFs in tumor microenvironment. This article reviews the origin, markers, and classification of CAFs, their impacts on the characteristics of NSCLC, and potential therapeutic targets of CAFs to help develop individualized treatment plans for NSCLC.
引用
收藏
页码:701 / 709
页数:9
相关论文
共 50 条
  • [21] Analysis of the immunological microenvironment at the tumor site in patients with non-small cell lung cancer
    Rui Li
    Dominik Rüttinger
    Rong Li
    Lü-Sheng Si
    Yi-Li Wang
    Langenbeck's Archives of Surgery, 2003, 388 : 406 - 412
  • [22] The tumor immune microenvironment in octogenarians with stage I non-small cell lung cancer
    Lee, Ming-Ching
    Buitrago, Daniel H.
    Kadota, Kyuichi
    Ujiie, Hideki
    Woo, Kaitlin
    Sima, Camelia S.
    Travis, William D.
    Jones, David R.
    Adusumilli, Prasad S.
    ONCOIMMUNOLOGY, 2014, 3 (11): : e967142 - 1
  • [23] Gefitinib in non-small cell lung cancer
    Tamura, K
    Fukuoka, M
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 985 - 993
  • [24] Immune microenvironment composition in non-small cell lung cancer and its association with survival
    Tamminga, Menno
    Hiltermann, Thijo Jeroen N.
    Schuuring, Ed
    Timens, Wim
    Fehrmann, Rudolf S. N.
    Groen, Harry J. M.
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2020, 9 (06)
  • [25] Oligoprogression in Non-Small Cell Lung Cancer
    Harada, Daijiro
    Takigawa, Nagio
    CANCERS, 2021, 13 (22)
  • [26] Angiogenesis and non-small cell lung cancer
    Cox, G
    Jones, JL
    Walker, RA
    Steward, WP
    O'Byrne, KJ
    LUNG CANCER, 2000, 27 (02) : 81 - 100
  • [27] Immunotherapy for non-small cell lung cancer
    Vafadar, Sam
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2019, 32 (09): : 37 - 42
  • [28] Ifosfamide in non-small cell lung cancer
    Boni, C
    Zanelli, F
    ONCOLOGY, 2003, 65 : 50 - 54
  • [29] Allelotype of non-small cell lung cancer
    Neville, EM
    Stewart, MP
    Swift, A
    Liloglou, T
    Ross, H
    Gosney, JR
    Donnelly, RJ
    Field, JK
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1996, 9 (03) : 533 - 539
  • [30] Docetaxel and non-small cell lung cancer
    Le Guen, Y
    Le Cesne, A
    BULLETIN DU CANCER, 2004, 91 (03) : 263 - 270